Additionally, we demonstrated that higher IL37 levels were associated with lower MSSS (p = 0.039), thus supporting the previously mentioned hypothesis that IL37 produced in response to ongoing immunoinflammatory events in MS might downregulate the progression of the disease. Here, IL37 is linked to myeloid sarcoma.